MAPT and Alzheimer disease: One of the strengths of the 3xTg-AD model is to offer the possibility to study, in the same animal, both Aβ and tau pathologies, which are significantly associated with the clinical expression of the disease, particularly when converted to their insoluble forms [33], [39]–[41].